Watchdog Group Blasts FDA’s Dwindling Oversight Of Non-Clinical Labs
This article was originally published in The Gray Sheet
Executive Summary
A nonprofit government watchdog group is criticizing FDA for scaling back inspections of laboratories that test medical devices early in the development process, before they are tested in humans
You may also be interested in...
510(k) Guidance Footnote May Signal Greater FDA Oversight Of Preclinical Testing
Device industry experts say a seemingly minor footnote to the recent 510(k) program draft guidance could create a new requirement for nonclinical studies.
Funding Advice From FDA Science Board: Double Total Over Next Five Budgets
FDA Science Board members recommend a nearly $1.9 billion direct appropriation for the agency in fiscal 2009, a $375 million increase over 2008, and larger increases in each of the following five federal budgets
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.